MedPath

Adamis Pharmaceuticals Corporation

🇺🇸United States
Ownership
-
Established
2006-01-01
Employees
131
Market Cap
-
Website
http://www.adamispharmaceuticals.com/

Clinical Trials

4

Active:0
Completed:0

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:2

Drug Approvals

1

FDA:1

Drug Approvals

SYMJEPI

Approval Date
Feb 6, 2019
FDA

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Phase 1
1 (25.0%)
Phase 2
1 (25.0%)

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Phase 2
Terminated
Conditions
Covid19
Interventions
Other: Placebo
First Posted Date
2021-01-28
Last Posted Date
2022-12-06
Lead Sponsor
Adamis Pharmaceuticals Corporation
Target Recruit Count
248
Registration Number
NCT04729595
Locations
🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇺🇸

LA Universal Research, Los Angeles, California, United States

🇺🇸

Doral medical Research, Doral, Florida, United States

and more 14 locations

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Phase 3
Withdrawn
Conditions
Asthma
Interventions
Drug: 400 µg per day Beclomethasone
Drug: Placebo
Drug: 200 µg per day Beclomethasone
Drug: 100 µg per day Beclomethasone
First Posted Date
2019-02-11
Last Posted Date
2019-07-17
Lead Sponsor
Adamis Pharmaceuticals Corporation
Registration Number
NCT03835871

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Phase 3
Withdrawn
Conditions
Asthma
Interventions
Drug: Beclomethasone 800 µg per day
Drug: Beclomethasone 640 µg per day
Drug: Placebo
Drug: Beclomethasone 400 µg per day
First Posted Date
2019-02-07
Last Posted Date
2019-07-17
Lead Sponsor
Adamis Pharmaceuticals Corporation
Registration Number
NCT03834012

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Phase 1
Conditions
Prostate Cancer
Interventions
First Posted Date
2011-09-19
Last Posted Date
2015-07-16
Lead Sponsor
Adamis Pharmaceuticals Corporation
Target Recruit Count
60
Registration Number
NCT01436214
Locations
🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.